$0.676
-0.004 (-0.63%)At close
IRIX News
IRIX Events
Iridex Publishes Glaucoma Laser Therapy Study Results
Iridex announced the publication of a two-year clinical study demonstrating outcomes with transscleral laser therapy, or TLT, using MicroPulse Technology in patients with early, moderate, and advanced primary glaucoma. Published in the International Journal of Ophthalmology, the retrospective study evaluated 84 eyes of 53 patients with primary open-angle glaucoma, or POAG, or primary angle-closure glaucoma, or PACG. Patients with prior incisional glaucoma surgery were excluded, while those who had undergone selective laser trabeculoplasty, or SLT, more than three years earlier remained eligible for inclusion. Mean intraocular pressure, or IOP, decreased significantly from 22.32 mmHg at baseline to 14.05 mmHg, with reductions sustained throughout the two-year follow-up. Mean number of topical IOP-lowering medications decreased from 2.96 at baseline to 2.38. Treatment success rates were 86% in POAG eyes and 81% in PACG eyes. No complications or reductions in visual acuity were reported during follow-up. Additional findings included the discontinuation of oral acetazolamide among all patients receiving the medication before MicroPulse TLT, with none requiring reinitiation during the two-year follow-up period. Further, visual field measurements remained stable during follow-up in both the POAG and PACG groups.
Iridex Partners with EyeProGPO for Laser Pricing
Iridex announced a new partnership with EyeProGPO. Through this partnership, the 1,800 plus EyeProGPO members can receive preferred pricing on the Iridex Pascal laser platform, IQ 532 and IQ 577 lasers, and the OcuLight TX laser.
Iridex Relocates Headquarters to San Jose, Expects $400K Savings
Iridex announced its intent to relocate the Company's headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for a new lease. The Company plans to move to the 31,000 square feet location and is expecting to generate savings of approximately $0.4 million in fiscal year 2026 and approximately $0.6 million in savings on an annualized basis thereafter. The terms of the Lease remain subject to change, and the Company cannot provide any guarantee that the Lease will be executed upon these same terms or at all.
IRIDEX Expects Total Revenue of $14.6M to $14.8M in 2025
Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%. "In 2025, we strengthened our financial position through focused cost reductions, gross margin expansion, and improved commercial efficiency, and increased probe sales," said Patrick Mercer, President and CEO of IRIDEX. "When we set and communicated our goals for 2025, we were clear about what we intended to accomplish-and in 2025 we delivered. The actions we took drove a fifth consecutive quarter of year-over-year revenue growth, reduced operating expenses, and improved adjusted EBITDA. We achieved positive cash flow in the fourth quarter of 2025, and we expect to achieve positive adjusted EBITDA for the full year 2025."
Iridex Study Shows 25%-35% IOP Reduction in Glaucoma Patients Using MicroPulse Technology
Iridex announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of transscleral laser treatment using MicroPulse technology can safely and effectively further reduce intraocular pressure, or IOP, in patients with glaucoma. The study aimed to assess the effectiveness, repeatability, and safety of retreatment in real-world clinical practice using MicroPulse TLT. Three months after retreatment, all patient groups demonstrated meaningful IOP reductions, ranging from approximately 25% to 35%, regardless of their prior response to the primary treatment. Retreatment timing varied widely across patient groups, reflecting the individualized nature of glaucoma management. On average, patients received their first retreatment as early as approximately 4 months in nonresponders and as late as more than 28 months in patients with late-attrition. Among the subset of patients who required a second retreatment, intervals ranged from about 3 months to nearly 2 years in enhancement cases.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.